You are now leaving NeulastaHCP.com

Please be aware that the sponsors of this site are not responsible for content on the site you are about to enter.

Return to Previous Page Continue to External Site

Prevalence of Clinically Significant Febrile Neutropenia

An estimated 60,000 cancer patients in the United States were hospitalized for chemotherapy-induced febrile neutropenia in 1999.1

—Adapted from Vogel C, et al. J Clin Oncol. 2005.
  • *Febrile neutropenia = ANC <0.5 x 109/L and temperature ≥38.2° C.

    • References

    1. Caggiano V, Weiss R, Rickert T, Linde-Zwirble W. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916-1924.
    2. Vogel C, Wojtukiewicz M, Carroll R, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-1184.